Gadofosveset trisodium


DB06705



General information:


Withdrawn ID: DB06705
Canonical SMILES:
Standard InChI:
Standard InChIKey:
ATC class(es): V08CA11
Molecular Formula: C33H38GdN3Na3O14P
Molweight: 957.87



Withdrawal information:


Withdrawn due to drug safety reasons:No
First withdrawn: 2009
Reference: https://www.ema.europa.eu/en/medicines/human/EPAR/ablavar-previously-vasovist



Side-effects:

Total reported cases (submitted by medical professionals) with Gadofosveset trisodium as primary suspect: 25


Reported final outcomes:
Hospitalization (initial or prolonged): 4
Life-Threatening condition: 2
Death: 1


Reported side-effects:

Side-effect Case number
NAUSEA7
BURNING SENSATION5
FEELING HOT3
PRURITUS3
GENITAL BURNING SENSATION3
CARDIO-RESPIRATORY ARREST3
URTICARIA2
THROAT TIGHTNESS2
DYSPNOEA2
VOMITING2
PRURITUS GENITAL2
Hyperhidrosis2
VULVOVAGINAL BURNING SENSATION1
Pharyngeal oedema1
POST PROCEDURAL COMPLICATION1
Pulseless electrical activity1
RASH1
RASH MACULAR1
Respiratory arrest1
RESTLESSNESS1
Ventricular extrasystoles1
SALIVARY HYPERSECRETION1
Labile blood pressure1
Sinus tachycardia1
SYNCOPE1
Tachycardia1
THROAT IRRITATION1
Uterine spasm1
Extrasystoles1
ANAL PRURITUS1
Atrial fibrillation1
Back pain1
Blood creatinine increased1
Blood urea increased1
BUDD-CHIARI SYNDROME1
Chest pain1
Dialysis1
Electrocardiogram ST segment depression1
LOSS OF CONSCIOUSNESS1
Flushing1
GENITAL ERYTHEMA1
Glomerular filtration rate decreased1
GROIN PAIN1
HEADACHE1
Hypertonic bladder1
Hypoaesthesia1
Abdominal pain upper1
Leukocytosis1





Toxicity information:



External links:

ChEBML: CHEMBL1908362